India, April 9 -- Zentalis Pharmaceuticals, Inc. (ZNTL) announced that 400mg once daily on a 5-days-on, 2-days-off schedule (400mg QD 5:2) has been selected as the pivotal monotherapy dose of Azenosertib in patients with Cyclin E1-positive platinum-resistant ovarian cancer (PROC).
The decision follows a prespecified interim analysis from the ongoing DENALI Part 2a trial, which showed a clearly differentiated response rate at 400mg compared to 300mg, with comparable safety profiles.
Clinical Significance
Azenosertib is a first-in-class, oral WEE1 inhibitor designed to target Cyclin E1-positive PROC, a biomarker-selected population that represents about half of patients with this difficult-to-treat cancer. Current therapies rely on intrave...